에스지헬스케어 Stock: price and insider trades · South Korea
No insider purchase over the last 90 days. The latest, by 임재현, was filed 09 Jul 2026.
에스지헬스케어: what insiders have been doing
에스지헬스케어 belongs to the Health Care sector. Filings by its managers are published through DART (FSS). Over the twelve months to 2 November 2026, 3 filings were filed, from 2 insiders.
Only purchases show up on the open market, 2 purchases in all, filed by 1 insider. The amount is not disclosed for 2 filings. Unlike grants, an open-market purchase is paid for by the insider, at the market price. On the buying side, the filings list 1 senior executive among the declarants.
The last insider purchase was made public on 9 July 2026, 124 days ago.
For context, the typical company on the same exchange (median of 2,655 companies) published 7 filings over the same period, against 3 filings here. Looking back to 2024, when coverage begins, insiders filed 5 purchases and no sales.
Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and UCB. Source: insider filings from DART (FSS). Past trades are no guide to future returns.
Who traded when
BuySaleTransparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- 6,250 sharesShareKRXDART:20260709000032Canonical exit: 7 Oct 2026 (T+90)
- 28,750 sharesShareKRXDART:20260708000087Canonical exit: 6 Oct 2026 (T+90)
- ●Executives0DART
- Other0DART
- Other0DART
- 3,565,288 sharesKRXDART:20241227000363Canonical exit: 19 Mar 2025 (T+90)
- 450,000 sharesKRXDART:20241227000276Canonical exit: 19 Mar 2025 (T+90)
- 3,396,288 sharesShareKRXDART:20241224000594Canonical exit: 24 Mar 2025 (T+90)
8 of 8 declarations
About 에스지헬스케어
Listed on the XKRX market, 에스지헬스케어 specializes in the healthcare and pharmaceutical sector. The company is dedicated to improving healthcare through innovative solutions.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
